EUVIMEDEUVIMED entdecken
Beobachtungsstudie

The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies

Kirk D Beebe, Joel R Eisner, John Guo iD, Yoichiro Shibata iD, James M Davison iD, Josh Uronis, Carol Farhangfar iD, Farhang Farhangfar iD, Jill Mooney, Michael V Milburn, Richard L White iD, Asim Amin und 2 weitere

The Journal of Immunology · 2024

DOI: 10.4049/jimmunol.2300736 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Kirk D Beebe und 13 weiteren Autor:innen. Beteiligte Einrichtung: GeneCentric Therapeutics, Inc., Durham, NC. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Interleukin-2, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-dose (HD) IL-2 was the first immuno-oncology agent approved for treating advanced renal cell carcinoma and metastatic melanoma, but its use was limited because of substantial toxicities. Multiple next-generation IL-2 agents are being developed to improve tolerability. However, a knowledge gap still exists for the genomic markers that define the target pharmacology for HD IL-2 itself. In this retrospective observational study, we collected PBMC samples from 23 patients with metastatic renal cell carcinoma who were treated with HD IL-2 between 2009 and 2015. We previously reported the results of flow cytometry analyses. In this study, we report the results of our RNA-sequencing immunogenomic survey, which was performed on bulk PBMC samples from immediately before (day 1), during (day 3), and after treatment (day 5) in cycle 1 and/or cycle 2 of the first course of HD IL-2. As part of a detailed analysis of immunogenomic response to HD IL-2 treatment, we analyzed the changes in individual genes and immune gene signatures. By day 3, most lymphoid cell types had transiently decreased, whereas myeloid transcripts increased. Although most genes and/or signatures generally returned to pretreatment expression levels by day 5, certain ones representative of B cell, NK cell, and T cell proliferation and effector functions continued to increase, along with B cell (but not T cell) oligoclonal expansion. Regulatory T cells progressively expanded during and after treatment. They showed strong negative correlation with myeloid effector cells. This detailed RNA-sequencing immunogenomic survey of IL-2 pharmacology complements results of prior flow cytometry analyses. These data provide valuable pharmacological context for assessing PBMC gene expression data from patients dosed with IL-2–related compounds that are currently in development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellInterleukin-2Kidney NeoplasmsImmunotherapyHumansMaleMiddle AgedFemaleAgedRetrospective StudiesAdultLeukocytes, MononuclearNeoplasm Metastasis

Substanzen

Interleukin-2

Autor:innen und Institutionen

  • GeneCentric Therapeutics, Inc., Durham, NC.
  • Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Synthorx - A Sanofi Company, La Jolla, CA.

ORCID-Profile: John Guo, Yoichiro Shibata, James M Davison, Carol Farhangfar, Farhang Farhangfar, Richard L White, Marcos E Milla, David M Foureau

Zitieren

APA

Beebe, K. D., Eisner, J. R., Guo, J., Shibata, Y., Davison, J. M., Uronis, J., Farhangfar, C., Farhangfar, F., Mooney, J., Milburn, M. V., White, R. L., Amin, A., Milla, M. E., & Foureau, D. M. (2024). The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300736

Vancouver

Beebe KD, Eisner JR, Guo J, Shibata Y, Davison JM, Uronis J, et al. The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300736

BibTeX
@article{Beebe2024,
  author = {Beebe, Kirk D and Eisner, Joel R and Guo, John and Shibata, Yoichiro and Davison, James M and Uronis, Josh and Farhangfar, Carol and Farhangfar, Farhang and Mooney, Jill and Milburn, Michael V and White, Richard L and Amin, Asim and Milla, Marcos E and Foureau, David M},
  title = {The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies},
  journal = {The Journal of Immunology},
  year = {2024},
  doi = {10.4049/jimmunol.2300736}
}
Kostenlos starten →